Topical application of St John's wort (Hypericum perforatum L.) and of its metabolite hyperforin inhibits the allostimulatory capacity of epidermal cells

British Journal of Dermatology

Volumn 142, Issue 5, 2000, Pages 979-984

  Schempp, C M ^a   Winghofer, B ^a   Ludtke R ^b   Simon Haarhaus, B ^a   Schopf E ^a   Simon, J C ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Hyperforin; Hypericin; Mixed epidermal cell lymphocyte reaction; Solar simulated radiation

Indexed keywords

HYPERFORIN;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFECT; EPIDERMIS CELL; FEMALE; HUMAN; HYPERICUM PERFORATUM; MALE; PRIORITY JOURNAL; SKIN INFLAMMATION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, TOPICAL; ANTI-BACTERIAL AGENTS; BICYCLO COMPOUNDS; CELL DIVISION; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIDERMIS; HUMANS; HYPERICUM; IMMUNITY, CELLULAR; IMMUNOSUPPRESSIVE AGENTS; ISOANTIGENS; LEUKOCYTES, MONONUCLEAR; PHLOROGLUCINOL; PLANTS, MEDICINAL; PROSPECTIVE STUDIES; T-LYMPHOCYTES; TERPENES;

EID: 0034103796     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.2000.03482.x     Document Type: Article

References (24)

1. 1 Meruelo D, Lavie G, Lavie D. Therapeutic agents with dramatic antiretroviral activity and little toxicity at effective doses: aromatic polycyclic diones hypericin and pseudohypericin. Proc Natl Acad Sci USA 1988; 85: 5230-4.
2. 2 Lavie G, Valentine F, Levin B et al. Studies of the mechanisms of action of the antiretroviral agents hypericin and pseudohypericin. Proc Natl Acad Sci USA 1989; 86: 5963-7.
3. 3 Linde K, Ramirez G, Muirow CD et al. St John's wort for depression - an overview and meta-analysis of randomized clinical trials. Br Med J 1996; 313: 253-8.
4. 4 Roth L. Hypericum - Hypericin. Landsberg/Lech. Germany: Ecomed. 1990: 96-9.
5. 5 Duran N, Song PS. Hypericin and its photodynamic action. Photochem Photobiol 1986; 43: 677-80.
6. 6 Bystrov NS, Chernov BK, Dobrynin VN, Kolosov MN. The structure of hyperforin. Tetrahedron Lett 1975; 32: 2791-4.
7. 7 Erdelmeier CAJ. Hyperforin, possibly the major non-nitrogenous secondary metabolite of Hypericum perforatum L. Pharmacopsychiatry 1998; 31 (Suppl. 1): 2-6.
8. 8 Pace N. The etiology of hypericism, a photosensitivity produced by St. John's wort. Am J Physiol 1942; 136: 650-6.
9. 9 Giese AC. Hypericism. Photochem Photobiol Rev 1980; 5: 229-55.
10. 10 Araya OS, Ford EJH. An investigation of the type of photosensitization caused by the ingestion of St John's wort (Hypericum perforatum) by calves. J Comp Pathol 1981; 91: 135-41.
11. 11 Thomas C, Randall S, MacGill S et al. Photoactivation of hypericin generates singlet oxygen in mitochondria and inhibits succinyloxidase. Photochem Photobiol 1992; 55: 47-53.
12. 12 Hadjur C, Richard MJ, Parat MO et al. Photodynamic effects of hypericin on lipid peroxidation and antioxidant status in melanoma cells. Photochem Photobiol 1996; 64: 375-81.
13. 13 Gurevich AI, Dobrynin VN, Kolosov MN et al. Hyperforin, an antibiotic from Hypericum perforatum L. Antibiotiki 1971; 16: 510-13.
14. 14 Schempp CM, Pelz K, Wittmer A et al. Antibacterial activity of hyperforin from Saint John's wort, against multiresistant Staphylococcus aureus and gram-positive bacteria. Lancet 1999; 353: 2129.
15. 15 Maisenbacher P, Kovar KA. Analysis and stability of Hyperici oleum. Planta Med 1992; 58: 351-4.
16. 16 Lomagno P, Lomagno RC. Activity of Hypericum perforatum oil in the treatment of the bedsores in old people. Fitoterapia 1979; 50: 201-5.
17. 17 Koulu L, Jansen CT. Effect of oral methoxsalen photochemotherapy on human Langerhans cell number. Dose-response and time-sequence studies. Arch Dermatol Res 1982; 274: 79-83.
18. 18 Morhenn VB, Orenberg EK, Kaplan J et al. Inhibition of Langerhans cell-mediated immune response by treatment modalities useful in psoriasis. J Invest Dermatol 1983; 81: 3-27.
19. 19 Murphy GM, Norris PG, Young AR et al. Low-dose ultraviolet-B irradiation depletes human epidermal Langerhans cells. Br J Dermatol 1993; 129: 674-7.
20. 20 Schempp CM, Simon-Haarhaus B, Heine A et al. In vitro and in vivo activation of hypericin with the incoherent light source PDT 1200 SOA (520-750 nm) and with solar simulated radiation (290-2500 nm). Photodermatol Photoimmunol Photomed 1999; 15: 13-17.
21. 21 Fitzpatrick TB. The validity and practicality of sun-reactive skin types I through VI. Arch Dermatol 1988; 124: 869-71.
22. 22 Weiss JM, Renkl AC, Denfeld RW et al. Low-dose UVB radiation perturbs the functional expression of B71 and B72 co-stimulatory molecules on human Langerhans cells. Eur J Immunol 1995; 25: 2858-62.
23. 23 Dittmar HC, Weiss JM, Termeer CC et al. In vivo UVA-1 and UVB irradiation differentially perturbs the antigen presenting function of human epidermal Langerhans cells. J Invest Dermatol 1999; 112: 322-5.
24. 24 Müller WE, Singer A, Wonnemann M et al. Hyperforin represents the neurotransmitter reuptake inhibiting constituent of Hypericum extract. Pharmacopsychiatry 1998; 31 (Suppl. 1): 16-21.